RedDress wins innovative technology contract from Vizient

JACKSONVILLE, Fla., Oct. 4, 2022 (GLOBE NEWSWIRE) — RedDress, a privately held U.S. and Israel-based global medical device company with a suite of advanced wound care products, today announced that it has received a U.S. lead The health care company Vizient, Inc.’s contract care performance improvement company, serves more than half of U.S. health care organizations. Awarded upon the recommendation of RedDress wound care products by hospital experts serving on one of Vizient member-led committees, the contract demonstrates to Vizient members unique qualities that may improve the healthcare industry.

After reviewing and interacting with products submitted through Vizient’s Innovative Technology Program, innovative technology contracts are recommended. Vizient member-led committees identify technologies that have the potential to enhance clinical care, patient safety, health care worker safety, or improve the business operations of health care organizations.

“We are delighted to offer our advanced autologous wound care products to Vizient’s many healthcare facility members. Our ActiGraft product suite is designed to benefit both clinicians and patients, and to help healthcare facilities reduce the risk of injury associated with healing chronic wounds. cost,” said RedDress managing director Robert Mueller.

The agreement brings RedDress’ ActiGraft product suite into greater access to Vizient’s membership, which consists of academic medical centers, community hospitals, integrated health care networks and non-acute healthcare providers. Available solutions include:

  • ActiGraft® System: The original autologous point-of-care management system that enables healthcare providers to generate extracorporeal blood clots from a patient’s whole blood in real time
  • ActiGraft+® System: An updated version of our flagship product that uses a proprietary calcium gluconate powder to create whole blood clots.

“Receiving this contract after participating in the Innovation Technology Exchange last September is further recognition of ActiGraft’s potential to become the new standard of care for chronic wounds such as diabetic foot ulcers and pressure injuries. We look forward to continuing to improve patients through this agreement therapeutic effect,” said Russell Lalli, president of RedDress.

“Our committee of members reviewed and recommended the ActiGraft system for innovative technology contracts because of its potential to generate incremental change in healthcare,” said Kelly Flaharty, senior director of contracting processes at Vizient. “Congratulations to RedDress for achieving this contract status.”

Vizient represents a diverse membership base including academic medical centers, pediatric facilities, community hospitals, integrated health care networks and non-acute healthcare providers, with annual purchases exceeding $100 billion. Through its Innovative Technology Program, Vizient partners with member-led committees and task forces to evaluate products’ potential to bring true innovation to healthcare. Vizient may award contracts outside of the competitive bidding cycle to products deemed worthy of innovative technology designation.

About ActiGraft

Based on RedDress’ proprietary patented technology, ActiGraft is an FDA-approved wound care solution that enables healthcare providers to generate extracorporeal blood clots from a patient’s whole blood in real time. Once applied, the blood clot acts as a protective covering and supports the wound healing process that occurs naturally in the patient.

ActiGraft is used for oozing skin wounds. ActiGraft includes blood contact components that have been sterilized with ethylene oxide, which may cause severe allergic reactions in sensitized patients. For complete prescribing information, visit

About the red coat

RedDress ( is a privately held company headquartered in Israel and its US subsidiary RedDress Inc. is located in Ponte Vedra Beach, Florida. Founded in 2009 to develop more effective, natural and economically viable treatments for chronic wounds, RedDress is committed to improving the health and lives of patients worldwide through its latest innovation, ActiGraft.


The ActiGraft® system is a registered trademark of RedDress Ltd.


Source link